We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Petros Pharmaceuticals Inc (PTPI) USD0.0001

Sell:$0.59 Buy:$0.61 Change: $0.0379 (6.91%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$0.59
Buy:$0.61
Change: $0.0379 (6.91%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
Sell:$0.59
Buy:$0.61
Change: $0.0379 (6.91%)
Market closed |  Prices as at close on 17 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.

Contact details

Address:
1185 Avenue Of The Americas
3Rd Floor, Suite 570
NEW YORK
10036
United States
Telephone:
+1 (973) 2420005
Website:
https://www.petrospharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PTPI
ISIN:
US71678J2096
Market cap:
$3.55 million
Shares in issue:
6.88 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Shulman
    Executive Chairman of the Board
  • Fady Boctor
    President, Chief Commercial Officer
  • Mitchell Arnold
    Chief Accounting Officer, Vice President - Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.